cytarabine has been researched along with 5'-oleoyl cytarabine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hartmann, HR; Hengartner, H; Rubas, W; Schott, H; Schwendener, R; Supersaxo, A; Weder, HG | 1 |
| Balzarini, J; Breistøl, K; De Clercq, E; Fodstad, O; Martinsen, M; Myhren, F; Sandvold, ML | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Aamdal, S; Dueland, S; Gaullier, JM; Lind, MJ; Rasch, W; Sandvold, ML; Thomas, H | 1 |
| Galmarini, CM; Myhren, F; Sandvold, ML | 1 |
| Adema, AD; Fichtner, I; Laan, AC; Myhren, F; Peters, GJ; Sandvold, ML; Verheul, HM | 1 |
| Galmarini, C; Myhren, F; Peters, G; Sandvold, ML | 1 |
| Adema, AD; Kathmann, I; Losekoot, N; Myhren, F; Peters, GJ; Sandvold, ML; Smid, K | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Amant, F; Breda, E; Cannella, L; Hernes, K; Leunen, K; Lorusso, D; Pignata, S; Pisano, C; Rasch, W; Scambia, G; Sorio, R; Vergote, I | 1 |
| Adema, AD; Honeywell, RJ; Losekoot, N; Myhren, F; Peters, GJ; Sandvold, ML; Smid, K; Verheul, HM | 1 |
| Burke, AC; Giles, FJ | 1 |
| Borthakur, G; Giles, FJ; Hagen, S; Jacobsen, TF; Nilsson, B; O'Brien, S; Prebet, T; Ravandi, F; Rizzieri, D; Vey, N | 1 |
| Giles, F; Jacobsen, TF; O'Brien, S; Ravandi, F; Rizzieri, D; Swords, R | 1 |
| Bergeland, T; Berry, DA; Dennis, M; Giles, FJ; Jacobsen, TF; Krug, UO; O'Brien, S; Ravandi, F; Rizzieri, DA; Sekeres, MA; Staudacher, K; Venditti, A; Vey, N | 1 |
| Freeman, C; Giles, FJ; Keane, N; Swords, R | 1 |
| DiNardo, CD; Gandhi, VV; O'Brien, S; Ravandi, F | 1 |
| Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML | 1 |
| Bergeland, T; Blau, IW; Gianella-Borradori, A; Gjertsen, BT; Huguet-Rigal, F; Jacobsen, TF; Johansen, M; Kindler, T; Krauter, J; Krug, U; Rizzieri, D; Schlenk, RF; Thomas, X; Vey, N | 1 |
| Bergua, JM; Chevassut, T; Duarte, R; Gianella-Borradori, A; Hals, PA; Jacobsen, TF; Johansen, M; Knapper, S; Rasch, W; Salamero, O; Smith, M | 1 |
| Altman, JK; Arellano, M; Foss, Ø; Gianella-Borradori, A; Giles, FJ; Gobbi, M; Hills, R; Jacobsen, TF; Montesinos, P; O'Connell, C; Pigneux, A; Roboz, GJ; Rosenblat, T; Solomon, SR; Vetrhusand, S; Vey, N | 1 |
3 review(s) available for cytarabine and 5'-oleoyl cytarabine
| Article | Year |
|---|---|
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cytarabine; Drug Delivery Systems; Drug Discovery; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy | 2011 |
Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Delivery Systems; Drug Discovery; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy | 2013 |
7 trial(s) available for cytarabine and 5'-oleoyl cytarabine
| Article | Year |
|---|---|
Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms | 2009 |
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Middle Aged; Ovarian Neoplasms | 2011 |
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytarabine; Female; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Young Adult | 2012 |
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Referral and Consultation; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Treatment Outcome | 2012 |
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cholesterol; Cytarabine; Drug Administration Schedule; Electrocardiography; Female; Heart; Humans; Leukemia, Myeloid, Acute; Lipoproteins; Male; Middle Aged; Recurrence; Treatment Outcome | 2014 |
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Hyperbilirubinemia; Hypercholesterolemia; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Treatment Failure | 2014 |
11 other study(ies) available for cytarabine and 5'-oleoyl cytarabine
| Article | Year |
|---|---|
Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Topics: Animals; Bone Marrow; Cytarabine; Female; Leukemia L1210; Liposomes; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA | 1986 |
Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Carcinoma; Carrier Proteins; Cytarabine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fatty Acids, Unsaturated; Female; Humans; Leukemia L1210; Leukemia, Experimental; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nucleoside Transport Proteins; Rats; Rats, Nude; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.
Topics: Cell Line, Tumor; Cell Membrane; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma | 2009 |
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Chemistry, Pharmaceutical; Cytarabine; Deoxycytidine; Docetaxel; Drug Design; Drug Screening Assays, Antitumor; Fatty Acids; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2010 |
The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; HT29 Cells; Humans; Pyrimidines | 2010 |
Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Nucleoside Deaminases; Polymerase Chain Reaction | 2010 |
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
Topics: Antineoplastic Agents; Cell Line; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Nucleoside Transport Proteins; Nucleotidases | 2012 |
Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.
Topics: Adult; Cytarabine; Hematologic Neoplasms; Humans; Middle Aged; Prognosis; Tissue Distribution | 2012 |
Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.
Topics: Cytarabine; Drug Approval; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cytarabine; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |